If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  FDA Advisory Committee Recommends Approval for Centocor's Myoscint MALVERN, Pa., Jan. 26, 1996 -- Centocor, Inc. (Nasdaq-NNM: CNTO) announced today that the Food and Drug Administration, Cardiovascular and Renal Drugs Advisory Committee has reviewed the safety and efficacy of Myoscint(R), and has recommended approval for imaging in the setting of chest pain, suspected to be caused by myocardial infarction. "We are extremely pleased with this recommendation from the Committee. It is further confirmation of Centocor's regulatory capability," said David P. Holveck, president and chief executive officer of Centocor, Inc. "With this recommendation of Myoscint, Centocor continues to build on its success in researching and developing new and innovative biotechnology products. Myoscint, if approved for marketing in the U.S., compliments our profitable Diagnostics Division." Myoscint is a monoclonal antibody which reacts to heavy chain myosin following myocardial cell death. Myoscint has received marketing approval in several European countries, where Centocor is a biotechnology company that develops therapeutic and diagnostic human health care products for cardiovascular, autoimmune and infectious diseases, and cancer. The company concentrates on research and development, manufacturing and market development, with a primary technological focus on monoclonal antibodies, with additional programs in gene vaccines and peptides. Centocor's press releases are available at no charge through PR Newswire's Company News On-Call fax service and on PRN's Web site. For a menu of available Centocor press releases or to retrieve a specific release, call 800-758-5804, ext. 150550, or http://www.prnewswire.com on the Internet. CONTACT: Investors, Madeline Hopkins, 610-651-6122, or Paul Wulfing,
|
